see what spruce biosciences is doing about treatment options for classic Congenital Adrenal Hyperplasia (CAH).

Spruce Biosciences is sponsoring a randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of tildacerfont in adults with classic congenital adrenal hyperplasia, followed by an open-label treatment with tildacerfont.
​
Click here to learn more details about the study.

Visit the trial website to see if you qualify to enroll in the studies: www.CAHstudy.com.